Lily Zou, Degron Therapeutics CEO
Armed with library of molecular glues, Degron launches out of a Shanghai lab
A transpacific biotech focused on molecular glues now has more funds to play with as it works to vie for Big Pharma’s attention.
Degron Therapeutics …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
